New insider Nodelman Oleg claimed ownership of 15,720,161 shares (SEC Form 3)
$ZYME
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 02/17/2025 |
3. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 15,720,161 | I | See Note(1) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Pre-Funded Warrants | 12/26/2023 | (2) | Common Stock | 5,086,521(3) | $0.0001 | I | See Note(1) |
| Explanation of Responses: |
| 1. Mr. Nodelman is the manager and controlling owner of EcoR1 Capital, LLC which is the investment adviser and general partner of private funds. The funds hold these securities directy for the benefit of their investors. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1 Capital, LLC. Mr. Nodelman disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| 2. The pre-funded warrants do not have an expiration date. |
| 3. Each pre-funded warrant is exercisable to purchase one share of Common Stock, except that the pre-funded warrants cannot be exercised if, after giving effect or immediately prior to such exercise, the reporting person, together with its affiliates and any other persons whose beneficial ownership of shares of Common Stock would be aggregated with the reporting person for purposes of Section 13(d) of the Securities Exchange Act of 1934, would beneficially own more than 19.99% of the total number of issued and outstanding shares of Common Stock or voting power of the Company following such exercise. |
| Remarks: |
| Mr. Nodelman is filing this Form 3 to report that he was appointed to the issuer's board of directors on February 17, 2025. Mr. Nodelman previously reported his beneficial ownership of the securities included in this report in the Forms 3 and Forms 4 filed by EcoR1 Capital, LLC. |
| /s/ Oleg Nodelman | 02/18/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||